NASPGHAN 2025 Recap: Pediatric GI Advances in H. pylori, IBS-C Treatments, and Liver Disease

Описание: Explore key highlights from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting. Discover geographic patterns of Helicobacter pylori in pediatric digestive diseases like eosinophilic esophagitis and inflammatory bowel disease. Learn about newly approved treatments for irritable bowel syndrome with constipation (IBS-C), including linaclotide and tenapanor safety data. Dive into long-term benefits of odevixibat for cholestatic liver diseases such as FIC1 deficiency and Alagille syndrome, focusing on pruritus reduction, bile acid control, and improved quality of life.
This video recaps expert interviews and research updates from clinicians and researchers at the conference. Topics include H. pylori prevalence, FDA approvals for pediatric therapies, and sustained improvements in sleep and caregiver quality of life. Stay informed on the latest in pediatric gastroenterology, hepatology, and nutrition.
Key areas covered:
Helicobacter pylori infection in children with EoE, celiac disease, and IBD
Long-term safety of linaclotide for pediatric IBS-C
Tolerability of tenapanor in adolescents with constipation
Odevixibat's role in managing pruritus and bile acids in progressive familial intrahepatic cholestasis
Perfect for pediatric gastroenterologists, nurses, and anyone interested in pediatric health updates. Subscribe for more medical conference recaps and expert insights.